RESEARCHER PROFILE
Dr Mark Adams, Senior Research Fellow
School of Biomedical Sciences & Centre for Genomics and Personalised Health
Queensland University of Technology (QUT)
Dr. Mark Adams is a researcher at Queensland University of Technology, working within the School of Biomedical Sciences and Faculty of Health, as well as the Centre of Genomics and Personalised Health. He has been with the university for the past decade, and his main research focus is on lung cancers. Dr. Adams completed his undergraduate studies at the Queensland University of Technology and then went on to earn his PhD based at the Mater Research Institute at the Mater hospital. His PhD focused on prostate cancer and specifically looked at developing drugs that would stop the metastasis of prostate cancer towards the bone.
After completing his PhD, Dr. Adams returned to Queensland University of Technology to commence a postdoctoral fellowship. During his fellowship, he looked at lung cancer and how our genomes are maintained through a process called DNA repair. Dr. Adams has been successful in attracting funding to support his salary through fellowship support from foundations such as Cure Cancer, National Health and Medical Research Council, and the Queensland government.
Dr. Adams’ research focus is on lung cancer, which is the deadliest of all cancers worldwide. He is working towards developing personalised approaches to pinpoint a therapy that is going to be most effective for the person with that disease. Dr. Adams’ research is focusing on chemotherapy and targeted therapy, and he is trying to identify upfront which of those tumours are likely to be resistant to the therapy. He then identifies strategies that will resensitize or increase the sensitivity of the tumour to the standard of care that is targeted therapy or chemotherapy.
Dr. Adams’ research is driven by his fascination with trying to understand how something works and, in particular, understanding cells and the molecular mechanisms underpinning how those cells work. He has always been interested in biology and was drawn to the problem of cancer and what’s going on in those tumour cells that promote tumorigenesis.
Dr. Adams has a young family with three kids, all in primary school. He enjoys downhill mountain biking in the forest and playing futsal on Monday nights.
You Might also like
-
Next Generation Condom Contraception, Dr Simon Cook
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
-
Development of novel analytical and diagnostic tools using nanotechnology and microfluidics
Dr Alain Wuethrich is an NHMRC Emerging Leader fellow and ARC DECRA awardee at the Australian Institute for Bioengineering and Nanotechnology.
Hailing from Switzerland, research focuses on the development of novel analytical and diagnostic tools that harness nanotechnology and microfluidics; two rapidly growing fields with high potential to provide diagnostic solutions needed for precision medicine.
-
Optimising Rural Musculoskeletal Health
Adnan Asger Ali is a Director of Accelerate Physiotherapy and PhD candidate at The University of Sydney, where he is researching implementation strategies for musculoskeletal care pathways in rural Australia as part of the PACE-RURAL project.
A passionate advocate for physiotherapy, Adnan serves as Chair of the Australian Physiotherapy Association’s National Musculoskeletal Committee and sits on the Capital Health Network’s Clinical Council. His commitment to clinical excellence was recognised when he received Physiotherapist of the Year at the 2023 Allied Health Awards.